26759-52-4

Usage

InChI:InChI=1/C10H9NO5S/c1-16-9(12)10(13)5-17-8-3-2-6(11(14)15)4-7(8)10/h2-4,13H,5H2,1H3

Upstream product

• 26759-51-3 methyl 2-[(2-methoxy-2-oxoethyl)thio]-5-nitrobenzoate 
• 6307-82-0 2-chloro-5-nitro-benzoic acid methyl ester 
• 2365-48-2 Methyl thioglycolate 

Downstream Products

• 26791-97-9 methyl 3-methoxy-5-nitrobenzo[b]thiophene-3-carboxylate 
• 26759-54-6 3-methoxy-5-nitrobenzo[b]thiophene-3-carboxylic acid 

Relevant academic research and scientific papers

HETEROCYCLIC DERIVATIVES AND USE THEREOF

A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein.

PROTEIN KINASE D INHIBITORS

Compounds according to Formula (I), are potent inhibitors of protein kinase D (pan-PKD) activity. PKD controls key signaling cascades in cells, affecting cell proliferation, gene transcription, and protein trafficking. Accordingly, pharmaceutically acceptable compositions of the inventive compounds are candidate therapeutics for pathological conditions conditioned by changes in PKD activity.

Synthesis and structure-activity relationships of benzothienothiazepinone inhibitors of protein kinase D

Protein kinase D (PKD) is a member of a novel family of serine/threonine kinases that regulate fundamental cellular processes. PKD is implicated in the pathogenesis of several diseases, including cancer. Progress in understanding the biological functions and therapeutic potential of PKD has been hampered by the lack of specific inhibitors. The benzoxoloazepinolone CID755673 was recently identified as the first potent and selective PKD inhibitor. The study of structure-activity relationships (SAR) of this lead compound led to further improvements in PKD1 potency. We describe herein the synthesis and biological evaluation of novel benzothienothiazepinone analogues. We achieved a 10-fold increase in the in vitro PKD1 inhibitory potency for the second generation lead kb-NB142-70 and accomplished a transition to an almost equally potent novel pyrimidine scaffold, while maintaining excellent target selectivity. These promising results will guide the design of pharmacological tools to dissect PKD function and pave the way for the development of potential anticancer agents.

3-Alkoxy-thianapthene-2-carboxamides

The 3-alkoxy-thianaphthene-2-carboxamides of this invention are effective for the treatment of mammals afflicted with emesis. When administered to dogs in dosages of 250 μg/kg, compounds of this invention give 100% protection against vomiting normally induced by subcutaneous administration of apomorphine. The compounds of this invention also favorably modify behavior disturbances in mammals.